BR112018008838A2 - método para tratar, prevenir, melhorar ou administrar uma doença epiléptica - Google Patents
método para tratar, prevenir, melhorar ou administrar uma doença epilépticaInfo
- Publication number
- BR112018008838A2 BR112018008838A2 BR112018008838-2A BR112018008838A BR112018008838A2 BR 112018008838 A2 BR112018008838 A2 BR 112018008838A2 BR 112018008838 A BR112018008838 A BR 112018008838A BR 112018008838 A2 BR112018008838 A2 BR 112018008838A2
- Authority
- BR
- Brazil
- Prior art keywords
- ameliorating
- treating
- preventing
- administering
- epileptic disorder
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4245—Oxadiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Abstract
são aqui fornecidos métodos de tratamento, prevenção, melhoramento ou gestão de uma doença epiléptica mediada por mutação nonsense, compreendendo a administração de um ácido benzoico 1,2,4-oxadiazol a um paciente com uma doença epiléptica mediada por mutação nonsense. em particular, são aqui proporcionados métodos de tratamento, prevenção, melhoramento ou gestão de uma doença epiléptica mediada por mutação em cdkl5 e/ou scn1a (síndrome de dravet) nonsense.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201562248891P | 2015-10-30 | 2015-10-30 | |
US62/248,891 | 2015-10-30 | ||
PCT/US2016/059262 WO2017075312A1 (en) | 2015-10-30 | 2016-10-28 | Methods for treating epilepsy |
Publications (2)
Publication Number | Publication Date |
---|---|
BR112018008838A2 true BR112018008838A2 (pt) | 2018-11-06 |
BR112018008838A8 BR112018008838A8 (pt) | 2019-02-26 |
Family
ID=58632013
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112018008838A BR112018008838A8 (pt) | 2015-10-30 | 2016-10-28 | método para tratar, prevenir, melhorar ou administrar uma doença epiléptica |
Country Status (15)
Country | Link |
---|---|
US (2) | US10517853B2 (pt) |
EP (1) | EP3368042A4 (pt) |
JP (1) | JP2018531975A (pt) |
KR (1) | KR20180081516A (pt) |
CN (1) | CN108348527A (pt) |
AR (1) | AR106530A1 (pt) |
BR (1) | BR112018008838A8 (pt) |
CA (1) | CA3003132A1 (pt) |
CO (1) | CO2018004684A2 (pt) |
HK (1) | HK1251965A1 (pt) |
IL (1) | IL258988A (pt) |
MX (1) | MX2018005361A (pt) |
PH (1) | PH12018500885A1 (pt) |
TW (1) | TW201729807A (pt) |
WO (1) | WO2017075312A1 (pt) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP6923517B2 (ja) | 2015-10-09 | 2021-08-18 | ユニバーシティ・オブ・サザンプトン | 遺伝子発現の調節及び脱制御されたタンパク質発現のスクリーニング |
JP7049248B2 (ja) | 2015-12-14 | 2022-04-06 | コールド スプリング ハーバー ラボラトリー | 常染色体優性精神遅滞-5とドラベ症候群の処置のためのアンチセンスオリゴマー |
SG11202001590RA (en) | 2017-08-25 | 2020-03-30 | Stoke Therapeutics Inc | Antisense oligomers for treatment of conditions and diseases |
US11301527B2 (en) | 2019-05-06 | 2022-04-12 | Acto Technologies Inc. | Event-driven content recommendation engine |
US11129829B2 (en) | 2019-06-17 | 2021-09-28 | Skyhawk Therapeutics, Inc. | Methods for modulating splicing |
MX2022011483A (es) * | 2020-03-17 | 2022-10-07 | Sumitomo Pharma Co Ltd | Derivado de oxadiazol. |
AU2021270720A1 (en) | 2020-05-11 | 2022-12-08 | Stoke Therapeutics, Inc. | OPA1 antisense oligomers for treatment of conditions and diseases |
CN117987538A (zh) * | 2024-04-07 | 2024-05-07 | 北京诺禾致源科技股份有限公司 | 用于检测depdc5突变基因的试剂在制备诊断或预测家族性局灶性癫痫伴可变灶1型的试剂盒中的应用 |
Family Cites Families (79)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NL291628A (pt) | 1962-04-17 | |||
US4022901A (en) | 1975-03-05 | 1977-05-10 | E. R. Squibb & Sons, Inc. | 3-Pyridinyl-5-isothiocyanophenyl oxadiazoles |
US4016170A (en) | 1975-07-28 | 1977-04-05 | Sandoz, Inc. | Oxadiazolyl benzamides |
US4166732A (en) | 1977-05-12 | 1979-09-04 | Monsanto Company | Oxadiazol-5-yl-benzoates |
US4135910A (en) | 1977-05-12 | 1979-01-23 | Monsanto Company | Oxadiazol-3-yl-benzoates as plant growth regulants |
US4210762A (en) | 1978-08-17 | 1980-07-01 | Monsanto Company | 2[5-(3-Trifluoromethylphenyl)-1,3,4-oxadiazol-2-yl] benzoates |
US4268299A (en) | 1978-08-17 | 1981-05-19 | Monsanto Company | Method and composition for plant growth regulation containing trifluoromethyl 1,3,4 oxadiazol benzoates |
US5484944A (en) | 1993-10-27 | 1996-01-16 | Neurogen Corporation | Certain fused pyrrolecarboxanilides and their use as GABA brain receptor ligands |
TW343965B (en) | 1994-03-30 | 1998-11-01 | Hoffmann La Roche | Novel mono- and bicyclic DNA gyrase inhibitors |
US6071700A (en) | 1995-01-20 | 2000-06-06 | University Of Massachusetts | Heterologous polypeptide production in the absence of nonsense-mediated MRNA decay functions |
EP0853626A1 (en) | 1995-09-07 | 1998-07-22 | Novartis AG | Substituted phosphinic compounds and their use as pharmaceuticals |
AU2405897A (en) | 1996-04-26 | 1997-11-19 | Nippon Soda Co., Ltd. | Novel heterocycle-substituted benzene derivatives and herbicides |
DE19620041A1 (de) | 1996-05-17 | 1998-01-29 | Merck Patent Gmbh | Adhäsionsrezeptor-Antagonisten |
WO1997046556A1 (en) | 1996-06-07 | 1997-12-11 | Merck & Co., Inc. | OXADIAZOLE BENZENESULFONAMIDES AS SELECTIVE β3 AGONISTS FOR THE TREATMENT OF DIABETES AND OBESITY |
US6034106A (en) | 1996-06-07 | 2000-03-07 | Merck & Co., Inc. | Oxadiazole benzenesulfonamides as selective β3 Agonist for the treatment of Diabetes and Obesity |
DE19626318A1 (de) | 1996-07-01 | 1998-01-08 | Basf Ag | Farbstoffmischungen, enthaltend Polyazofarbstoffe |
ZA98371B (en) | 1997-01-31 | 1999-07-16 | Du Pont | Genetically transformed plants demonstrating resistance to porphyrinogen biosynthesis-inhibiting herbicides. |
EP0975595B9 (en) | 1997-04-07 | 2009-09-16 | Georgetown University | Analogs of cocaine |
US6004933A (en) | 1997-04-25 | 1999-12-21 | Cortech Inc. | Cysteine protease inhibitors |
AU9647998A (en) | 1997-10-27 | 1999-05-17 | Nippon Soda Co., Ltd. | Novel benzoylpyrazole derivatives and herbicides |
WO1999054317A1 (en) | 1998-04-23 | 1999-10-28 | Cortech Inc. | Cysteine protease inhibitors |
EA200100428A1 (ru) | 1998-10-08 | 2001-10-22 | Смитклайн Бичам Плс | Производные тетрагидробензазепина, полезные в качестве модуляторов допаминовых d3 рецепторов (антипсихотические агенты) |
AU763460B2 (en) | 1998-10-09 | 2003-07-24 | Janssen Pharmaceutica N.V. | 4,5-dihydro-isoxazole derivatives and their pharmaceutical use |
AU1455500A (en) | 1998-10-29 | 2000-05-22 | Trega Biosciences, Inc. | Oxadiazole, thiadiazole and triazole derivatives and combinatorial libraries thereof |
PL350132A1 (en) | 1998-12-23 | 2002-11-04 | Smithkline Beecham Corp | Protease inhibitors |
WO2000058304A1 (fr) | 1999-03-26 | 2000-10-05 | Shionogi & Co., Ltd. | Derives sulfonamides heterocycliques |
WO2000058280A1 (fr) | 1999-03-26 | 2000-10-05 | Shionogi & Co., Ltd. | Derives de sulfonamide carbocyclique |
AU3196200A (en) | 1999-03-26 | 2000-10-16 | Shionogi & Co., Ltd. | Beta-amino acid derivatives |
EP1183229B1 (en) | 1999-05-17 | 2005-10-26 | Novo Nordisk A/S | Glucagon antagonists/inverse agonists |
UA71971C2 (en) | 1999-06-04 | 2005-01-17 | Agoron Pharmaceuticals Inc | Diaminothiazoles, composition based thereon, a method for modulation of protein kinases activity, a method for the treatment of diseases mediated by protein kinases |
JP2001247569A (ja) | 1999-08-12 | 2001-09-11 | Japan Tobacco Inc | ピロリジン誘導体又はピペリジン誘導体及びその医薬用途 |
US6660753B2 (en) | 1999-08-19 | 2003-12-09 | Nps Pharmaceuticals, Inc. | Heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists |
WO2001066534A2 (en) | 2000-03-09 | 2001-09-13 | Abbott Laboratories | Cyclic and bicyclic diamino histamine-3 receptor antagonists |
CA2401984A1 (en) | 2000-03-22 | 2001-09-27 | Merck Frosst Canada Inc. | Sulfur substituted aryldifluoromethylphosphonic acids as ptp-1b inhibitors |
WO2001083464A1 (fr) | 2000-04-21 | 2001-11-08 | Shionogi & Co., Ltd. | Derives d'oxadiazole efficaces en matiere de traitement ou de prevention d'etats pathologiques glomerulaire |
GB0011089D0 (en) | 2000-05-08 | 2000-06-28 | Black James Foundation | Gastrin and cholecystokinin receptor ligands (11) |
CN1230431C (zh) | 2000-05-22 | 2005-12-07 | 阿温蒂斯药物公司 | 用作类胰蛋白酶抑制剂的芳基甲胺衍生物 |
JP2002105073A (ja) | 2000-09-27 | 2002-04-10 | Shionogi & Co Ltd | 新規マトリックスメタロプロテアーゼ阻害剤 |
AUPR362001A0 (en) | 2001-03-08 | 2001-04-05 | Fujisawa Pharmaceutical Co., Ltd. | New compound |
CA2342432A1 (en) | 2001-03-28 | 2002-09-28 | Christopher Norbert Johnson | Novel compound |
GB0108102D0 (en) | 2001-03-30 | 2001-05-23 | Pfizer Ltd | Compounds |
MXPA03009548A (es) | 2001-04-19 | 2004-05-24 | Bayer Ag | Arilsulfonamidas como agentes antivirales. |
CA2449544A1 (en) | 2001-06-08 | 2002-12-19 | Cytovia, Inc. | Substituted 3-aryl-5-aryl-[1,2,4]-oxadiazoles and analogs |
JP2003081832A (ja) | 2001-06-26 | 2003-03-19 | Takeda Chem Ind Ltd | レチノイド関連受容体機能調節剤 |
GB0115862D0 (en) | 2001-06-28 | 2001-08-22 | Smithkline Beecham Plc | Compounds |
MY151199A (en) | 2001-11-02 | 2014-04-30 | Rigel Pharmaceuticals Inc | Substituted diphenyl heterocycles useful for treating hcv infection |
CN1691944A (zh) | 2002-08-09 | 2005-11-02 | 阿斯利康(瑞典)有限公司 | 作为代谢型谷氨酸受体-5调节剂的噁二唑 |
CA2495179A1 (en) | 2002-08-09 | 2004-02-19 | Astrazeneca Ab | Compounds having an activity at metabotropic glutamate receptors |
GB0303503D0 (en) | 2003-02-14 | 2003-03-19 | Novartis Ag | Organic compounds |
AU2003901425A0 (en) * | 2003-03-27 | 2003-04-10 | Bionomics Limited | A diagnostic method for epilepsy |
CN1795177A (zh) | 2003-03-28 | 2006-06-28 | 辉瑞产品公司 | 作为治疗动脉粥样硬化和肥胖症的cetp抑制剂的 1 , 2 , 4 , -取代的1,2,3,4,-四氢-和1,2二氢-喹啉以及1, 2 , 3 , 4-四氢-喹喔啉衍生物 |
HUE031794T2 (en) | 2003-04-11 | 2017-08-28 | Ptc Therapeutics Inc | 1,2,4-oxadiol-benzoic acid compounds and their use for nonsense suppression and disease treatment |
US20050075375A1 (en) | 2003-05-14 | 2005-04-07 | Anadys Pharmaceuticals, Inc. | Heterocyclic compounds for treating hepatitis C virus |
WO2005060961A2 (en) | 2003-12-18 | 2005-07-07 | Astrazeneca Ab | Treatment of transient lower esophageal sphincter relaxations (tlesrs) and gastro-esophageal reflux disease (gerd) |
US7745630B2 (en) | 2003-12-22 | 2010-06-29 | Justin Stephen Bryans | Triazolyl piperidine arginine vasopressin receptor modulators |
WO2005077373A2 (en) | 2004-02-03 | 2005-08-25 | Astrazeneca Ab | Treatment of gastro-esophageal reflux disease (gerd) |
EP2363129A1 (en) | 2004-10-13 | 2011-09-07 | PTC Therapeutics, Inc. | Pyrazole or triazole compounds and their use for the manufacture of a medicament for treating somatic mutation-related diseases |
ES2390804T3 (es) | 2005-04-08 | 2012-11-16 | Ptc Therapeutics, Inc. | Composiciones de un 1,2,4-oxadiazol oralmente activo para terapia de supresión de la mutación sin sentido |
CN101193632A (zh) * | 2005-04-08 | 2008-06-04 | Ptc医疗公司 | 用于无义突变抑制治疗的口服活性1,2,4-噁二唑组合物 |
CA2612180A1 (en) * | 2005-06-16 | 2006-12-21 | Bionomics Limited | Methods of treatment, and diagnosis of epilepsy by detecting mutations in the scn1a gene |
EP2007365A2 (en) | 2006-03-30 | 2008-12-31 | PTC Therapeutics, Inc. | Methods for the production of functional protein from dna having a nonsense mutation and the treatment of disorders associated therewith |
WO2007123848A2 (en) | 2006-04-19 | 2007-11-01 | Brown University | Therapeutic compositions containing modified class i slrp proteins |
CA2662749C (en) | 2006-09-08 | 2015-01-20 | Ptc Therapeutics, Inc. | Processes for the preparation of 1,2,4-oxadiazole benzoic acids |
AU2007300542B2 (en) | 2006-09-25 | 2012-05-17 | Ptc Therapeutics, Inc. | Crystalline forms of 3-[5-(2-fluorophenyl)-[1,2,4]oxadiazol-3-yl]-benzoic acid |
US8101641B2 (en) | 2006-09-25 | 2012-01-24 | Ptc Therapeutics, Inc. | Hydroxylated 1,2,4-oxadiazole benzoic acid compounds and compositions thereof |
JP2010506840A (ja) | 2006-10-12 | 2010-03-04 | ピーティーシー セラピューティクス,インコーポレーテッド | ナンセンス突然変異抑制治療用の経口的に活性な1,2,4−オキサジアゾールの投与方法 |
WO2008127364A2 (en) | 2006-10-13 | 2008-10-23 | Myriad Genetics, Inc. | Antiviral compounds and use thereof |
US20110177999A1 (en) | 2007-08-09 | 2011-07-21 | Vertex Pharmaceuticals Incorporated | Therapeutic Combinations Useful in Treating CFTR Related Diseases |
US8202865B2 (en) | 2007-10-04 | 2012-06-19 | Merck Serono Sa | Oxadiazole derivatives |
HUE028662T2 (en) | 2007-10-26 | 2016-12-28 | Academisch Ziekenhuis Leiden | Preparations and methods for controlling muscle disorders |
EP2234625B8 (en) | 2007-12-17 | 2013-10-30 | The Regents of the University of Michigan | Compositions and methods for treating and preventing skeletal muscle deficiencies |
US8362050B2 (en) | 2008-06-24 | 2013-01-29 | Irm Llc | Compounds and methods for modulating G protein-coupled receptors |
NZ592717A (en) | 2008-10-07 | 2013-03-28 | Mpex Pharmaceuticals Inc | Aerosol fluoroquinolone formulations for improved pharmacokinetics comprising levofloxacin or ofloxacin and a di- or trivalent cation |
RU2398770C1 (ru) | 2009-03-27 | 2010-09-10 | Учреждение Российской академии наук Институт молекулярной генетики РАН (ИМГ РАН) | Меченная тритием 3-[5-(2-фторфенил)-1,2,4-оксадиазол-3-ил]бензойная кислота |
EP2241558A1 (en) * | 2009-04-03 | 2010-10-20 | Merck Serono SA | Oxadiazole derivatives |
US20120289476A1 (en) | 2009-12-11 | 2012-11-15 | Jay Allan Barth | Methods for treating methylmalonic acidemia |
EP2600865B1 (en) | 2010-08-05 | 2018-11-14 | Université de Lille | Compound useful for the treatment of nonsense-mutation-mediated diseases and pharmaceutical composition comprising said compound |
KR102497273B1 (ko) | 2014-03-06 | 2023-02-07 | 피티씨 테라퓨틱스, 인크. | 1,2,4-옥사디아졸 벤조산의 약학 조성물 및 염 |
WO2015188037A1 (en) | 2014-06-06 | 2015-12-10 | Ptc Therapeutics, Inc. | Methods of treatment using a 1,2,4-oxadiazole benzoic acid |
-
2016
- 2016-10-28 MX MX2018005361A patent/MX2018005361A/es unknown
- 2016-10-28 CA CA3003132A patent/CA3003132A1/en not_active Abandoned
- 2016-10-28 WO PCT/US2016/059262 patent/WO2017075312A1/en active Application Filing
- 2016-10-28 TW TW105135155A patent/TW201729807A/zh unknown
- 2016-10-28 JP JP2018522022A patent/JP2018531975A/ja active Pending
- 2016-10-28 KR KR1020187013165A patent/KR20180081516A/ko unknown
- 2016-10-28 BR BR112018008838A patent/BR112018008838A8/pt not_active Application Discontinuation
- 2016-10-28 AR ARP160103314A patent/AR106530A1/es unknown
- 2016-10-28 EP EP16860855.2A patent/EP3368042A4/en not_active Withdrawn
- 2016-10-28 US US15/771,379 patent/US10517853B2/en active Active
- 2016-10-28 CN CN201680063273.8A patent/CN108348527A/zh active Pending
-
2018
- 2018-04-25 PH PH12018500885A patent/PH12018500885A1/en unknown
- 2018-04-26 IL IL258988A patent/IL258988A/en unknown
- 2018-04-30 CO CONC2018/0004684A patent/CO2018004684A2/es unknown
- 2018-08-31 HK HK18111236.1A patent/HK1251965A1/zh unknown
-
2019
- 2019-11-07 US US16/676,806 patent/US20200188362A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
CA3003132A1 (en) | 2017-05-04 |
MX2018005361A (es) | 2018-06-07 |
IL258988A (en) | 2018-06-28 |
WO2017075312A1 (en) | 2017-05-04 |
BR112018008838A8 (pt) | 2019-02-26 |
US10517853B2 (en) | 2019-12-31 |
US20200188362A1 (en) | 2020-06-18 |
PH12018500885A1 (en) | 2018-10-29 |
US20180333397A1 (en) | 2018-11-22 |
CO2018004684A2 (es) | 2018-08-10 |
EP3368042A1 (en) | 2018-09-05 |
HK1251965A1 (zh) | 2019-05-10 |
JP2018531975A (ja) | 2018-11-01 |
TW201729807A (zh) | 2017-09-01 |
EP3368042A4 (en) | 2019-06-26 |
KR20180081516A (ko) | 2018-07-16 |
AR106530A1 (es) | 2018-01-24 |
CN108348527A (zh) | 2018-07-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR112018008838A2 (pt) | método para tratar, prevenir, melhorar ou administrar uma doença epiléptica | |
BR112017005693A2 (pt) | método para tratar e/ou prevenir uma doença hepática, e, composição farmacêutica. | |
BR112015009948A8 (pt) | Antagonistas de ativina-actrii, usos dos mesmos para tratamento de doenças ósseas e outros distúrbios e método para monitorar a eficácia do tratamento ou prevenção de uma doença óssea e outros distúrbios | |
BR112017004349A2 (pt) | terapia com gene de globina para o tratamento de hemoglobinopatias | |
BR112016016290A2 (pt) | Composições farmacêuticas de insulina de ação rápida, conjunto de infusão, sistema de conjunto de infusão e usos de análogos monoméricos ou diméricos de insulina | |
BR112015003397A2 (pt) | composto, composição farmacêutica, uso do composto e método para tratar uma doença ou condição mediada por rorgammat em um paciente. | |
BR112016020688A2 (pt) | Composições úteis no tratamento da deficiência da ornitina transcarbamilase (otc) | |
BR112015019064A2 (pt) | métodos de tratamento de melanoma | |
BR112015022197A2 (pt) | tratamento de cataplexia | |
BR112017000301A2 (pt) | tratamento de leucemia com inibidores de histona desacetilase | |
AR087918A1 (es) | Tratamientos combinados que comprenden antagonistas de c-met y antagonistas de b-raf | |
NI201000105A (es) | Régimen de dosificación asociado con ésteres de paliperidona inyectables de acción prolongada. | |
BR112015013349A2 (pt) | trieptanoína para o tratamento de deficiência de transportador de glicose 1 | |
BR112015023439A2 (pt) | combinação de tratamentos de câncer utilizando micrornas e inibidores egfr-tki | |
EA201890811A1 (ru) | Способы лечения мышечной дистрофии | |
BR112015010039A2 (pt) | tratamento de câncer com pomalidomida em um individuo com disfunção renal | |
EA201491702A1 (ru) | Оптимизированные терапевтические агенты для подкожного введения | |
BR112016007487A2 (pt) | composições compreendendo citrulina e leucina e seu uso no tratamento de diabetes e de síndrome meta-bólica | |
BR112022007721A2 (pt) | Método para o tratamento da demência | |
BR112017008805A2 (pt) | tratamento de córnea usando laminina | |
EA201592265A1 (ru) | Маркер для ассоциированных с кислой сфингомиелиназой нарушений и его применения | |
BR112013010345A2 (pt) | tratamento de diabetes melitus usando as injeções de insulina administradas com intervalos de variação da injeção | |
MY194135A (en) | Treatment and diagnosis of inflammatory disorders | |
AR097179A1 (es) | Tratamiento de la esclerosis múltiple con una combinación de laquinimod y flupirtina | |
RU2014142752A (ru) | Способы воздействия на экспрессию гена лактазы |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] |
Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS. |
|
B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
B11B | Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements |